Vancouver, British Columbia - Genix Pharmaceuticals Corporation (TSX-V: GENX; OTCQB: GENPF) ('GENIX' or the 'Company') is pleased to announce that it has recently received Health Canada registration approval and has been issued a Natural Product Number (NPN) for Rechlor (Renolchlor) - which aids in restoring kidney health and kidney functions naturally.

In 2020, Genix acquired the Canadian sales and marketing rights for Renochlor and will be renamed 'Rechlor' for the purpose of sales in the Canadian market. The NPN for Rechlor issued to Genix is 80112398 which has been approved for distribution to patients, naturopathic doctors and pharmacies throughout Canada. Rechlor is a clinically proven dietary supplement for improvement of renal functions in patients suffering from Chronic Renal Failure (CRF) and Chronic Kidney Disease (CKD). According to the Kidney Foundation of Canada, one-in-ten Canadians, or some 4 million people, suffer from kidney disease which if not treated will ultimately lead to kidney failure and the need for permanent dialysis or kidney transplant. Rechlor is the first-in-class natural over-the-counter product to effectively address both CKD and CRF with no known side effects or adverse reactions.

About Rechlor:

Protects kidneys from various nephrotoxins (renal toxicity) * Assists in reduction of serum creatinine and blood urea levels * Aid in improvement of glomerular filtration rate * A novel therapy for renal care * A dietary supplement acting as nephroprotective, antioxidant, immune booster * Clinical trials suggest improvement of quality of life in CRF patients

Contact:

Kevin Bottomley

Director

Tel: +1 (604) 609.6199

E: kbottomley@genixpharm.com

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, 'forward?looking statements'. Forward?looking statements may be identified by words including 'anticipates', 'believes', 'intends', 'estimates', 'expects' and similar expressions. The Company cautions readers that forward?looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward?looking statements.

(C) 2021 Electronic News Publishing, source ENP Newswire